Introduction: The Growing Need for Biomarkers in Diabetes Care

Diabetes mellitus, a spectrum of metabolic disorders defined by chronic hyperglycemia, remains one of the most pressing global health challenges. According to the International Diabetes Federation, over 537 million adults currently live with diabetes, and this number is projected to exceed 780 million by 2045. A key clinical hurdle is not merely diagnosing diabetes early but accurately tracking its progression from prediabetes to overt disease and through the development of complications. Traditional markers—such as fasting glucose, HbA1c, and oral glucose tolerance tests—provide valuable snapshots but often fail to capture the underlying metabolic and inflammatory shifts that drive disease progression. There is increasing interest in circulating metabolites as sensitive, dynamic, and mechanistically informative biomarkers. Among these, metabolites derived from the essential amino acid tryptophan have emerged as particularly promising candidates.

Recent research indicates that alterations in tryptophan metabolism are intimately linked with insulin resistance, β‑cell dysfunction, and the chronic low‑grade inflammation characteristic of type 2 diabetes. Circulating levels of tryptophan and its downstream products—such as kynurenine, serotonin, and various indole derivatives—reflect a convergence of host genetics, diet, gut microbiota activity, and immune status. As such, these metabolites may serve not only as biomarkers of disease progression but also as tools to stratify patients for personalized interventions. This article reviews the current understanding of circulating tryptophan metabolites in the context of diabetes, highlighting their potential as actionable biomarkers and discussing the steps needed for clinical translation.

The Tryptophan Metabolic Network: A Concise Overview

Tryptophan is an essential amino acid obtained from dietary protein. Only a small fraction of ingested tryptophan is used for protein synthesis; the majority is catabolized through three major pathways: the kynurenine pathway, the serotonin (5‑hydroxytryptamine) pathway, and the indole pathway mediated by the gut microbiota. Each branch yields a suite of bioactive molecules that influence immune responses, neurotransmission, and metabolic homeostasis.

The Kynurenine Pathway

Accounting for approximately 95% of tryptophan degradation, the kynurenine pathway is initiated by the rate‑limiting enzymes indoleamine 2,3‑dioxygenase (IDO) and tryptophan 2,3‑dioxygenase (TDO). IDO is induced by inflammatory cytokines such as interferon‑γ, linking immune activation to tryptophan catabolism. The pathway produces kynurenine, which is further metabolized to 3‑hydroxykynurenine, 3‑hydroxyanthranilic acid, quinolinic acid, and ultimately nicotinamide adenine dinucleotide (NAD+). Several of these intermediates—particularly quinolinic acid—are neuroactive and have pro‑oxidant or pro‑inflammatory properties. The kynurenine‑to‑tryptophan ratio is widely used as a surrogate for IDO activity and systemic immune activation.

The Serotonin Pathway

In enterochromaffin cells of the gut and, to a lesser extent, in the brain, tryptophan is hydroxylated by tryptophan hydroxylase to produce 5‑hydroxytryptophan, which is then decarboxylated to serotonin. Most of the body’s serotonin (90%) is synthesized in the gut, where it regulates motility, secretion, and mucosal immune responses. Serotonin itself is further metabolized to melatonin, a key regulator of circadian rhythms. Although serotonin’s role in metabolic regulation is less well understood than that of kynurenine, emerging evidence suggests that aberrant serotonin signaling is linked to insulin resistance and obesity.

The Indole Pathway

A smaller fraction of dietary tryptophan is converted by gut bacteria into indole and indole derivatives such as indole‑3‑acetic acid, indole‑3‑propionic acid, and indole‑3‑aldehyde. These compounds act as ligands for the aryl hydrocarbon receptor (AhR), a transcription factor that modulates immune responses and intestinal barrier integrity. Indole derivatives also influence glucose metabolism through effects on incretin secretion and hepatic gluconeogenesis. Because microbial composition varies widely among individuals, the levels of indole metabolites can differ substantially, making them both a source of inter‑individual variability and a potential marker of gut health.

Rewiring of Tryptophan Metabolism in Diabetes

Multiple cross‑sectional and prospective studies have demonstrated significant alterations in circulating tryptophan metabolites in individuals with prediabetes, newly diagnosed type 2 diabetes, and long‑standing disease. The most consistently reported changes involve the kynurenine pathway.

Elevated Kynurenine and IDO Activity

Plasma levels of kynurenine and the kynurenine‑to‑tryptophan ratio are typically higher in patients with type 2 diabetes compared with normoglycemic controls. This elevation is often associated with increased inflammatory markers such as C‑reactive protein, interleukin‑6, and tumor necrosis factor‑α. Mechanistic studies indicate that IDO activation contributes to insulin resistance by promoting the differentiation of pro‑inflammatory T‑helper 17 cells and by depleting tryptophan, which is required for normal β‑cell function. Moreover, downstream products of the kynurenine pathway, including 3‑hydroxykynurenine and quinolinic acid, can induce oxidative stress in pancreatic islets and impair insulin secretion. For example, a 2020 meta‑analysis published in Diabetes Care reported that a one‑unit increase in the kynurenine‑to‑tryptophan ratio was associated with a 30% higher risk of incident type 2 diabetes (Wang et al., 2020).

Alterations in Serotonin and Indole Derivatives

Serotonin levels in the circulation are often reduced in obesity and type 2 diabetes, possibly due to impaired gut‑derived synthesis or increased degradation by monoamine oxidase. Low circulating serotonin has been linked to delayed gastric emptying and reduced postprandial insulin secretion. Conversely, a subset of indole metabolites, particularly indole‑3‑acetic acid, are elevated in the serum of patients with type 2 diabetes and correlate positively with visceral adiposity and hepatic steatosis. Indole‑3‑propionic acid, on the other hand, appears to be lower in individuals with diabetes, suggesting that shifts in the microbial community—rather than a uniform increase—are relevant. A 2021 study from the Journal of Clinical Endocrinology & Metabolism found that a panel of tryptophan metabolites (including kynurenine, 3‑hydroxykynurenine, and indole‑3‑acetic acid) could distinguish individuals with prediabetes from healthy controls with an area under the curve of 0.85 (Pedersen et al., 2021).

Candidate Biomarkers for Diabetes Progression

Based on current evidence, several specific tryptophan metabolites and their ratios have been proposed as biomarkers for different aspects of diabetes progression—from early metabolic deterioration to the development of chronic complications.

Kynurenine‑to‑Tryptophan Ratio (K/T Ratio)

As mentioned, the K/T ratio is a robust indicator of IDO activity and systemic inflammation. It has been consistently associated with worsening glycemic control, higher HbA1c levels, and increased risk of microvascular complications. In longitudinal cohorts, a rising K/T ratio often precedes the transition from impaired glucose tolerance to overt diabetes, making it a candidate for early‑warning purposes. Because IDO is induced by inflammatory signals, the K/T ratio may also serve as a surrogate marker for the pro‑inflammatory milieu that drives insulin resistance.

Quinolinic Acid and 3‑Hydroxykynurenine

These downstream kynurenine metabolites are neurotoxic and have been implicated in diabetic neuropathy and cognitive decline. Elevated plasma quinolinic acid correlates with peripheral nerve dysfunction and may help stratify patients at risk for neuropathic complications. Additionally, 3‑hydroxykynurenine can generate reactive oxygen species and has been linked to oxidative damage in retinal cells, offering a potential early marker for diabetic retinopathy.

Indole‑3‑Acetic Acid and Indole‑3‑Propionic Acid

Indole‑3‑acetic acid, a gut microbiota‑derived metabolite, has been associated with insulin resistance and non‑alcoholic fatty liver disease in diabetes cohorts. Its levels may reflect alterations in gut permeability and endotoxemia. In contrast, indole‑3‑propionic acid appears to have protective effects; lower circulating levels are seen in patients with diabetic kidney disease. This reciprocal pattern suggests that the ratio of these two indole metabolites could be a more informative biomarker than either alone.

Serotonin and 5‑Hydroxyindoleacetic Acid

Although serotonin has received less attention as a diabetes biomarker, reduced fasting serotonin levels have been reported in patients with type 2 diabetes and are inversely correlated with insulin resistance. Measuring the primary serotonin metabolite 5‑hydroxyindoleacetic acid (5‑HIAA) in plasma or urine may provide additional insight into serotonin turnover. However, confounding by medications (e.g., SSRIs) and dietary intake limits the utility of serotonin‑based markers in routine practice.

Clinical Implications: From Prediction to Personalization

The integration of tryptophan metabolite profiling into clinical workflows holds several distinct advantages. First, these metabolites can be measured in plasma, serum, or dried blood spots using established techniques such as liquid chromatography‑tandem mass spectrometry (LC‑MS/MS), making them scalable for large‑scale screening. Their ability to capture both inflammatory and microbial dimensions of diabetes pathophysiology offers a more comprehensive picture than single biomarkers like HbA1c.

Second, because tryptophan metabolites respond to dietary interventions, weight loss, and pharmacological therapies (e.g., metformin, GLP‑1 receptor agonists), they could serve as pharmacodynamic markers to monitor treatment efficacy. For instance, metformin has been shown to reduce IDO activity and lower the K/T ratio, while bariatric surgery induces shifts in indole metabolite profiles that correlate with improved insulin sensitivity.

Third, tryptophan‑based biomarkers may enable early identification of patients at high risk for complications, allowing for preventive strategies. A patient with a persistently elevated K/T ratio and high quinolinic acid levels could be flagged for more intensive glycemic control and screening for neuropathy. In the era of precision medicine, incorporating such biomarkers into risk algorithms could refine the selection of therapeutic targets, such as using IDO inhibitors in individuals with evidence of excessive IDO activation.

Challenges and Considerations for Routine Implementation

Despite the promise, several hurdles must be overcome before circulating tryptophan metabolites can be adopted as standard clinical biomarkers. Variability due to diet, circadian rhythms, and gut microbiota composition is substantial; without standardized pre‑analytical conditions, reference ranges could differ widely across populations. Acute infections, autoimmune flares, and malignancies also influence IDO activity and metabolite levels, introducing confounding in unselected patient groups.

Another challenge is the complexity of the metabolic network. A single metabolite may be upstream or downstream of multiple enzymatic steps, and its levels can be affected by genetic polymorphisms in enzymes such as IDO1, TDO2, and kynurenine‑3‑monooxygenase. Multi‑metabolite panels (e.g., including kynurenine, 3‑hydroxykynurenine, quinolinic acid, indole‑3‑acetic acid, and serotonin) are likely to be more robust than any single marker, but they also increase cost and analytical complexity.

Furthermore, the lack of large‑scale prospective studies with standardized assays limits the evidence base for clinical decision‑making. Most existing studies are cross‑sectional or moderate in size, and they often do not account for medication use, renal function (since many metabolites are cleared renally), or ethnic differences. The American Diabetes Association has not yet included any tryptophan metabolite in its guidelines, reflecting the need for validation in diverse, real‑world populations.

Future Directions: Toward Translation

To move the field forward, coordinated efforts are needed. First, large, longitudinal cohort studies that measure a comprehensive panel of tryptophan metabolites at multiple time points—using harmonized LC‑MS/MS protocols—would clarify temporal relationships with glycemic deterioration, insulin resistance, and complication onset. Second, randomized controlled trials that examine whether metabolite‑guided therapy improves outcomes (e.g., earlier initiation of IDO inhibitors or gut‑targeted interventions) are required to demonstrate clinical utility.

Third, integration with other ‘omics platforms (genomics, proteomics, metagenomics) could unravel the causal pathways linking tryptophan metabolism to diabetes. For example, a Mendelian randomization study using single nucleotide polymorphisms in IDO1 and TDO2 could provide evidence for a causal role of the kynurenine pathway in insulin resistance. Fourth, advances in point‑of‑care technology—such as handheld metabolite sensors—could eventually enable real‑time monitoring of tryptophan metabolites in primary care settings.

Finally, interventional studies targeting the tryptophan metabolic axis—such as dietary modulation of tryptophan intake, use of prebiotics to alter indole production, or pharmacological inhibition of IDO—are needed to determine whether modifying these metabolites can alter the course of diabetes itself. A 2022 proof‑of‑concept trial in overweight individuals showed that a low‑tryptophan diet for four weeks reduced kynurenine levels and improved insulin sensitivity, but long‑term safety and efficacy remain unknown (Klaassen et al., 2022).

Conclusion

Circulating tryptophan metabolites, especially those of the kynurenine and indole pathways, represent a rich and mechanistically grounded class of biomarkers for diabetes progression. They reflect the underlying inflammatory, neuroactive, and microbial disturbances that accompany and even drive the transition from normoglycemia to overt disease and complications. The kynurenine‑to‑tryptophan ratio, quinolinic acid, and indole‑3‑acetic acid have shown particular promise in cross‑sectional and longitudinal studies. Yet, the full potential of these metabolites will only be realized through rigorous validation in diverse cohorts, standardization of analytical methods, and demonstration of clinical actionability. As metabolomics technologies continue to mature and become more accessible, integrating tryptophan metabolite panels into diabetes care could enhance risk stratification, personalize treatment, and ultimately improve long‑term outcomes for millions of patients worldwide.